Second press release today !!!!! Release #:812
Post# of 7805
(Total Views: 683)
Posted On: 08/19/2019 9:15:27 AM
Second press release today !!!!!
Release #:812-182891-rl-1235735:
(2) SAVED THIS IMPORTANT CHART FOR SEPARATE E-MAIL:
Current Development Status
"The New Technology for Neurological Disorders" Present the Following Market Opportunities:
US
Annual Potential
Product
Sufferers
Devices
Line
Neurological Disorder
Millions
Usage
Millions
Status
ActiPatch~
Musculoskeletal
125
3
375
FDA Approved for Knee, Full Musculoskeletal Pain Relief Pending
Smart InsoleTIII
Heel Pain
2
3
6
FDA Approved
Allay"
Menstrual Pain
37
1
37
Clinically Proven at Indiana University Medical School & University Hospital Birmingham
Reccvervgx"
Postoperative Pain
40
1
40
FDA Approved, To be Marketed to Mitigate Opioid Use
RecoveryRx$
Chronic Wounds
7
12
84
FDA Approved, To be Marketed as Pain Relief Bandages
RecoveryRxlil
Overactive Bladder
33
4
132
University Texas Medical School Clinical Trial
RecoveryRxE'J
Pelvic Pain
10
3
30
University Texas Medical School Clinical Trial
RecoveryRx®
Migraine Headaches
30
3
90
BioElectronics Internal Clinical Study
RecoveryRx<e)
Peripheral Neuropathy
20
4
80
Open
Total
874
The proper marketing and selling of medical devices requires experience management and the financial
resources to sustain an adequate product introduction. Even with adequate financing it would take
years to develop the management team. We are aggressively seeking qualified sales and marketing
partners.
8/19/2019 8:59:22 AM
Release #:812-182891-rl-1235735:
(2) SAVED THIS IMPORTANT CHART FOR SEPARATE E-MAIL:
Current Development Status
"The New Technology for Neurological Disorders" Present the Following Market Opportunities:
US
Annual Potential
Product
Sufferers
Devices
Line
Neurological Disorder
Millions
Usage
Millions
Status
ActiPatch~
Musculoskeletal
125
3
375
FDA Approved for Knee, Full Musculoskeletal Pain Relief Pending
Smart InsoleTIII
Heel Pain
2
3
6
FDA Approved
Allay"
Menstrual Pain
37
1
37
Clinically Proven at Indiana University Medical School & University Hospital Birmingham
Reccvervgx"
Postoperative Pain
40
1
40
FDA Approved, To be Marketed to Mitigate Opioid Use
RecoveryRx$
Chronic Wounds
7
12
84
FDA Approved, To be Marketed as Pain Relief Bandages
RecoveryRxlil
Overactive Bladder
33
4
132
University Texas Medical School Clinical Trial
RecoveryRxE'J
Pelvic Pain
10
3
30
University Texas Medical School Clinical Trial
RecoveryRx®
Migraine Headaches
30
3
90
BioElectronics Internal Clinical Study
RecoveryRx<e)
Peripheral Neuropathy
20
4
80
Open
Total
874
The proper marketing and selling of medical devices requires experience management and the financial
resources to sustain an adequate product introduction. Even with adequate financing it would take
years to develop the management team. We are aggressively seeking qualified sales and marketing
partners.
8/19/2019 8:59:22 AM
(1)
(0)BioElectronics Corporation (BIEL) Stock Research Links
Scroll down for more posts ▼